Financial & competing interests disclosure
James A Hamilton has equity in VascuVis Inc., formed to commercialize technology for the characterization of atherosclerotic plaque. This research was supported in part by NIH grant 5P50HL083801 (to James A Hamilton).The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.